Shanghai – – September 28, 2026 -- MOYOM Biotech, a Chinese developer of regenerative aesthetic biomaterials, has secured a new financing round from the Cathay Consumer Co-Creation Fund, managed by Cathay Capital, to fund international expansion of its flagship CaHA-based implant brand Aphranel®.
Cathay Capital Fund Backed by L'Oréal Targets Beauty and Skin Science Innovation
The investment vehicle was jointly established by Cathay Capital, L'Oréal and the Shanghai Jing'an District Government. Cathay Capital's broader portfolio includes Moonshot AI (Kimi), autonomous driving firm Momenta, U.S. fintech Chime, digital asset platform Ledger, delivery platform Glovo and AI biotech company Owkin.
Aphranel Already Operates in More Than 700 Chinese Clinics
Founded in 2018, MOYOM specializes in nanomedical biomaterials and Class III absorbable implantable medical devices centered on calcium hydroxylapatite (CaHA) regenerative materials. Aphranel®, positioned as a next-generation CaHA biostructurer, combines immediate structural support with regenerative stimulation and full biodegradation. Since its commercial launch in May 2025, the product has been adopted by over 700 medical aesthetics clinics across China.
Dual Patented Technologies Underpin the Product Platform
MOYOM's platform relies on two proprietary technologies: ACD-MT®, a raspberry-shaped through-hole CaHA microsphere system, and PCD-ETT®, a physically cross-linked CMC gel technology. The combination is engineered to deliver structural performance alongside controlled biodegradation and regenerative interaction.
Regulatory Clearances in China and the EU Open Path to Global Markets
Aphranel® received Class III medical device registration from China's National Medical Products Administration in February 2025, followed by certification under the EU Medical Device Regulation in May 2026. MOYOM plans to use the new capital to accelerate clinical translation, pursue further regulatory approvals and enter overseas markets while continuing investment in next-generation regenerative biomaterials.